Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 3/20 | 0.55 |
| ▸ | SYK | P43405 | 1/20 | 0.44 |
| ▸ | LCK | P06239 | 2/20 | 0.41 |
| ▸ | GSK3A | P49840 | 2/20 | 0.41 |
| ▸ | GSK3B | P49841 | 2/20 | 0.41 |
| ▸ | CDK7 | P50613 | 2/20 | 0.41 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.41 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | BTK | Q06187 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.40 |
| ▸ | G6PD | P11413 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 4/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1778705 | 0.89 | IGF1R (0.58) | IGF1RSYKRAB9ARIPK1G6PD | |
| SCHEMBL12606279 | 0.86 | SYK (0.55) | IGF1RSYKLCKGSK3AGSK3B | |
| SCHEMBL1778184 | 0.85 | RAB9A (0.49) | IGF1RSYKLCKGSK3AGSK3B | |
| SCHEMBL1748575 | 0.84 | IGF1R (0.68) | IGF1RSYKRIPK1MAPTSMN1; SMN2 | |
| SCHEMBL1777457 | 0.83 | G6PD (0.48) | IGF1RSYKLCKGSK3AGSK3B | |
| SCHEMBL1748730 | 0.83 | IGF1R (0.59) | IGF1RSYKRIPK1MAPTSMN1; SMN2 | |
| SCHEMBL1779688 | 0.82 | SYK (0.61) | IGF1RSYKLCKGSK3AGSK3B | |
| SCHEMBL1778941 | 0.82 | DRD2 (0.48) | IGF1RSYKLCKGSK3AGSK3B | |
| SCHEMBL1749496 | 0.80 | IGF1R (0.62) | IGF1RSYKRIPK1CDK9 | |
| SCHEMBL1749103 | 0.80 | IGF1R (0.80) | IGF1RSYKLCKGSK3AGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050267304-A1 | Protein kinase inhibitors; astham; psoriasis; antiinflammatory agents; inflammatory bowel disorders | AVENTIS PHARMACEUTICALS INC. (US) | 2005-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050267304-A1 | Protein kinase inhibitors; astham; psoriasis; antiinflammatory agents; inflammatory bowel disorders | MAP3K20, MAP3K12, MAP3K19 | IGF1R 1245/4885SYK 113/4885LCK 66/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.